Heska (NASDAQ:HSKA) Sees Large Volume Increase

Heska Co. (NASDAQ:HSKAGet Rating) saw an uptick in trading volume on Friday . 3,507 shares traded hands during mid-day trading, a decline of 97% from the previous session’s volume of 129,463 shares.The stock last traded at $73.16 and had previously closed at $73.47.

Analyst Ratings Changes

Several brokerages have recently weighed in on HSKA. Morgan Stanley downgraded shares of Heska from an “equal weight” rating to an “underweight” rating and set a $58.00 target price for the company. in a research note on Friday, January 6th. StockNews.com began coverage on shares of Heska in a research note on Wednesday, October 12th. They issued a “hold” rating for the company. Piper Sandler decreased their target price on shares of Heska from $170.00 to $165.00 and set an “overweight” rating for the company in a research note on Monday, November 14th. Alliance Global Partners decreased their target price on shares of Heska from $155.00 to $119.00 and set a “buy” rating for the company in a research note on Wednesday, November 9th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Heska from $175.00 to $150.00 and set an “overweight” rating for the company in a research note on Monday, October 17th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Heska presently has an average rating of “Hold” and a consensus price target of $123.00.

Heska Stock Up 6.8 %

The company has a current ratio of 7.18, a quick ratio of 5.61 and a debt-to-equity ratio of 0.24. The stock has a market capitalization of $849.72 million, a P/E ratio of -49.97 and a beta of 1.40. The stock’s 50 day simple moving average is $65.44 and its 200 day simple moving average is $77.48.

Heska (NASDAQ:HSKAGet Rating) last posted its quarterly earnings data on Tuesday, November 8th. The medical research company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.15. Heska had a negative net margin of 6.26% and a positive return on equity of 0.09%. The firm had revenue of $61.49 million for the quarter, compared to the consensus estimate of $69.72 million. As a group, research analysts predict that Heska Co. will post 0.26 EPS for the current fiscal year.

Insider Transactions at Heska

In other Heska news, CEO Kevin S. Wilson purchased 11,018 shares of Heska stock in a transaction dated Friday, January 6th. The shares were bought at an average cost of $58.62 per share, for a total transaction of $645,875.16. Following the transaction, the chief executive officer now owns 167,072 shares in the company, valued at approximately $9,793,760.64. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Heska news, CEO Kevin S. Wilson purchased 3,440 shares of Heska stock in a transaction dated Thursday, December 22nd. The shares were bought at an average cost of $59.64 per share, for a total transaction of $205,161.60. Following the transaction, the chief executive officer now owns 156,054 shares in the company, valued at approximately $9,307,060.56. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Kevin S. Wilson purchased 11,018 shares of Heska stock in a transaction dated Friday, January 6th. The stock was acquired at an average price of $58.62 per share, for a total transaction of $645,875.16. Following the completion of the transaction, the chief executive officer now owns 167,072 shares in the company, valued at approximately $9,793,760.64. The disclosure for this purchase can be found here. Insiders own 11.00% of the company’s stock.

Institutional Trading of Heska

Large investors have recently modified their holdings of the company. Lazard Asset Management LLC acquired a new stake in shares of Heska in the 2nd quarter worth about $39,000. Point72 Hong Kong Ltd acquired a new stake in shares of Heska in the 1st quarter worth about $57,000. Quantbot Technologies LP increased its holdings in shares of Heska by 245.6% in the 3rd quarter. Quantbot Technologies LP now owns 508 shares of the medical research company’s stock worth $37,000 after acquiring an additional 361 shares during the period. UBS Group AG increased its holdings in shares of Heska by 83.1% in the 3rd quarter. UBS Group AG now owns 1,703 shares of the medical research company’s stock worth $124,000 after acquiring an additional 773 shares during the period. Finally, Mutual of America Capital Management LLC increased its holdings in shares of Heska by 17.4% in the 2nd quarter. Mutual of America Capital Management LLC now owns 1,812 shares of the medical research company’s stock worth $171,000 after acquiring an additional 269 shares during the period. Institutional investors and hedge funds own 99.01% of the company’s stock.

Heska Company Profile

(Get Rating)

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers.

Featured Stories

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.